Skip to content
Commercial Litigation Woods Lonergan LLP

212.684.2500

Copyright Litigation

Novartis drug Promacta® receives FDA Breakthrough Therapy designation for first-line use in severe aplastic anemia ... - GlobeNewswire (press release)

January 4, 2018 - 1:15am

Novartis drug Promacta® receives FDA Breakthrough Therapy designation for first-line use in severe aplastic anemia ...
GlobeNewswire (press release)
In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory ...

and more »

Startup defies the rules by going it alone – till now - Business ... - Haaretz

January 3, 2018 - 8:19pm

Haaretz

Startup defies the rules by going it alone – till now - Business ...
Haaretz
Formed more than a decade ago, AlgoSec raises capital for the first time in a $36m fundraiser from Claridge Israel.

and more »

Tabula Rasa HealthCare Engaged to Provide Opioid Education and Interventions to Physicians with Patients at High ... - GlobeNewswire (press release)

January 3, 2018 - 5:11pm

FlintDaily.com

Tabula Rasa HealthCare Engaged to Provide Opioid Education and Interventions to Physicians with Patients at High ...
GlobeNewswire (press release)
Important factors that could cause actual results to differ materially include: the need to innovate and provide useful products and services; risks related to changing healthcare and other applicable regulations; increasing consolidation in the ...
Financial Newsletter - American Consumer News, LLCAmerican Consumer News, LLC

all 41 news articles »

Nuvectra Announces Analyst & Investor Meeting at NANS 2018 - GlobeNewswire (press release)

January 3, 2018 - 4:01pm

Nuvectra Announces Analyst & Investor Meeting at NANS 2018
GlobeNewswire (press release)
... (x) the scope of protection for our intellectual property rights covering Algovita and other products using our neurostimulation technology platform, along with any product enhancements or improvements; (xi) our ability to successfully build ...

and more »

UPDATE – Recro Pharma Announces Key Executive Promotions to the Financial Team - GlobeNewswire (press release)

January 3, 2018 - 11:16am

UPDATE – Recro Pharma Announces Key Executive Promotions to the Financial Team
GlobeNewswire (press release)
... financial goals, including financial guidance; the Company's ability to raise future financing for continued development, product commercialization and the payment of milestones; the Company's ability to pay its debt; customer product performance ...

and more »

InspireMD Announces Regulatory Approval of CGuard EPS in India ... - GlobeNewswire (press release)

January 3, 2018 - 8:56am

InspireMD Announces Regulatory Approval of CGuard EPS in India ...
GlobeNewswire (press release)
TEL AVIV, ISRAEL, Jan. 03, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that it has received regulatory approval ...

and more »

Zosano Pharma Announces Notice of Allowance for a U.S. Patent ... - GlobeNewswire (press release)

January 3, 2018 - 8:31am

Zosano Pharma Announces Notice of Allowance for a U.S. Patent ...
GlobeNewswire (press release)
FREMONT, Calif., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corp. (NASDAQ:ZSAN) (“Zosano” or the “Company”) a clinical stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to subjects using its ...

and more »

Avinger Announces Treatment of First Patients Globally With Next Generation Pantheris - GlobeNewswire (press release)

January 3, 2018 - 8:31am

Avinger Announces Treatment of First Patients Globally With Next Generation Pantheris
GlobeNewswire (press release)
These risks and uncertainties, many of which are beyond our control, include our dependency on a limited number of products; our ability to demonstrate the benefits of our Lumivascular platform; the resource requirements related to Pantheris; the ...

and more »

Mateon Therapeutics to Present at the 2018 Biotech Showcase - GlobeNewswire (press release)

January 3, 2018 - 7:30am

Mateon Therapeutics to Present at the 2018 Biotech Showcase
GlobeNewswire (press release)
Under the "Investors & News" tab, select the link to "Events & Presentations." A replay of the webcast will be available at this same location for a period of time following the conclusion of the live event. About Mateon Mateon Therapeutics, Inc. is a ...

and more »

Checkpoint Therapeutics to Present at Biotech Showcase™ 2018 - GlobeNewswire (press release)

January 3, 2018 - 7:30am

Checkpoint Therapeutics to Present at Biotech Showcase™ 2018
GlobeNewswire (press release)
... uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional ...

and more »

Actinium Pharmaceuticals to Present at Biotech Showcase™ 2018 ... - GlobeNewswire (press release)

January 3, 2018 - 7:30am

Actinium Pharmaceuticals to Present at Biotech Showcase™ 2018 ...
GlobeNewswire (press release)
NEW YORK, Jan. 03, 2018 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or "the Company") announced today that the Company will be attending the Biotech Showcase™ 2018 being held January 8-10, 2018 at the Hilton ...

and more »

Cytokinetics Announces Progress Against Vision 2020 - GlobeNewswire (press release)

January 3, 2018 - 7:30am

Cytokinetics Announces Progress Against Vision 2020
GlobeNewswire (press release)
Examples of such statements include, but are not limited to, statements relating to Cytokinetics' and its partners' research and development activities; the design, timing, results, significance and utility of preclinical and clinical results ...

and more »

Opthea Initiates OPT-302 Diabetic Macular Edema Clinical Trial ... - GlobeNewswire (press release)

January 3, 2018 - 5:30am

GlobeNewswire (press release)

Opthea Initiates OPT-302 Diabetic Macular Edema Clinical Trial ...
GlobeNewswire (press release)
This figure profiles the evaluation of OPT-302 in combination with aflibercept for persistent central-involved diabetic macular edema. Opthea Limited. MELBOURNE, Australia, Jan. 03, 2018 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a late stage ...

and more »

Novartis Kisqali® received FDA Breakthrough Therapy designation ... - GlobeNewswire (press release)

January 3, 2018 - 1:16am

Novartis Kisqali® received FDA Breakthrough Therapy designation ...
GlobeNewswire (press release)
Basel, January 3, 2018 - Novartis today announced Kisqali® (ribociclib) received US Food and Drug Administration (FDA) Breakthrough Therapy designation for initial endocrine-based treatment of pre- or perimenopausal women with hormone-receptor positive ...

and more »

Novartis Kisqali® received FDA Breakthrough Therapy designation ... - GlobeNewswire (press release)

January 3, 2018 - 1:16am

Novartis Kisqali® received FDA Breakthrough Therapy designation ...
GlobeNewswire (press release)
Basel, January 3, 2018 - Novartis today announced Kisqali® (ribociclib) received US Food and Drug Administration (FDA) Breakthrough Therapy designation for initial endocrine-based treatment of pre- or perimenopausal women with hormone-receptor positive ...

and more »

Novartis Kisqali® received FDA Breakthrough Therapy designation ... - GlobeNewswire (press release)

January 3, 2018 - 1:16am

Novartis Kisqali® received FDA Breakthrough Therapy designation ...
GlobeNewswire (press release)
Basel, January 3, 2018 - Novartis today announced Kisqali® (ribociclib) received US Food and Drug Administration (FDA) Breakthrough Therapy designation for initial endocrine-based treatment of pre- or perimenopausal women with hormone-receptor positive ...

and more »

Novartis Kisqali® received FDA Breakthrough Therapy designation ... - GlobeNewswire (press release)

January 3, 2018 - 1:16am

Novartis Kisqali® received FDA Breakthrough Therapy designation ...
GlobeNewswire (press release)
Basel, January 3, 2018 - Novartis today announced Kisqali® (ribociclib) received US Food and Drug Administration (FDA) Breakthrough Therapy designation for initial endocrine-based treatment of pre- or perimenopausal women with hormone-receptor positive ...

and more »

Novartis Kisqali® received FDA Breakthrough Therapy designation ... - GlobeNewswire (press release)

January 3, 2018 - 1:16am

Novartis Kisqali® received FDA Breakthrough Therapy designation ...
GlobeNewswire (press release)
Basel, January 3, 2018 - Novartis today announced Kisqali® (ribociclib) received US Food and Drug Administration (FDA) Breakthrough Therapy designation for initial endocrine-based treatment of pre- or perimenopausal women with hormone-receptor positive ...

and more »

Novartis Kisqali® received FDA Breakthrough Therapy designation for initial endocrine-based treatment in ... - GlobeNewswire (press release)

January 3, 2018 - 1:16am

Novartis Kisqali® received FDA Breakthrough Therapy designation for initial endocrine-based treatment in ...
GlobeNewswire (press release)
In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory ...

and more »

Novartis Kisqali® received FDA Breakthrough Therapy designation ... - GlobeNewswire (press release)

January 3, 2018 - 1:16am

Novartis Kisqali® received FDA Breakthrough Therapy designation ...
GlobeNewswire (press release)
Basel, January 3, 2018 - Novartis today announced Kisqali® (ribociclib) received US Food and Drug Administration (FDA) Breakthrough Therapy designation for initial endocrine-based treatment of pre- or perimenopausal women with hormone-receptor positive ...

and more »